The first full-course antiviral influenza therapy in a single intravenous dose approved for people 2 years and older.1

Ordering Information

Deliver full-course influenza therapy to patients in your care with RAPIVAB.

in a study, up to 55%

of adults were noncompliant when prescribed an oral antiviral medication3

Nearly 75%

of adults are nonadherent — from not filling prescriptions to taking fewer than the recommended dosages3

nearly one third

of patients stop taking their medicine earlier than instructed3

When oral influenza therapy is not appropriate, consider RAPIVAB.

Review RAPIVAB information here.

RAPIVAB is the first full course of antiviral influenza therapy in a single intravenous dose. RAPIVAB is FDA approved for people aged 2 and older and helps to treat acute uncomplicated influenza with just one 15- to 30-minute IV infusion.1

RAPIVAB is an influenza virus neuraminidase inhibitor indicated for the treatment of acute uncomplicated influenza in patients 2 years and older who have been symptomatic for no more than two days.

  • RAPIVAB injection is a clear, colorless, sterile, isotonic solution.
  • Each single-use vial contains 200 mg per 20 mL (10 mg/mL) of peramivir in a clear glass vial. RAPIVAB injection is supplied in cartons containing 3 single-use vials.

Store vials of RAPIVAB injection in original cartons at 20°C to 25°C (68°F to 77°F). Excursions are permitted to 15°C to 30°C (59°F to 86°F). Do not use if seal over bottle opening is broken or missing.

Ask about RAPIVAB® today.

Please call customer service at (855) 358-8966 for more information.

Please call customer service at (855) 358-8966 to order RAPIVAB® today


By creating an account with us, you can see specific product
pricing, make a purchase, and manage your shipments easily.